Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 177Lu-3050
177Lu-IM-3050 · 1 trial · 1 indication
Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 6.0, including adverse events (SAEs), AEs leading to discontinuation, and deaths
Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE criteria version 6.0, including SAEs, AEs leading to discontinuation, and deaths
| Arm | Type | Description |
|---|---|---|
| Dose Escalation: 177Lu-IM-3050 | EXPERIMENTAL | 177Lu-IM-3050 administered intravenously on a 6-week cycle |
| Dose Expansion: 177Lu-IM-3050 | EXPERIMENTAL | 177Lu-IM-3050 administered intravenously on a 6-week cycle |
| Name | Type | Description |
|---|---|---|
| 177Lu-IM-3050 | DRUG | 177Lu-IM-3050 is a FAP-directed radiopharmaceutical |
Inclusion Criteria: * ≥18 years of age * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1 or 2 * Histological or cytological diagnosis of a solid tumor * Participants must be refractory to or have relapsed after at least one prior standard therapeutic regimen. Participants mu...
177Lu-3050 is an investigational small molecule being developed for the treatment of solid malignancies. It is currently in early clinical development, with a Phase 1 study evaluating its safety and efficacy in participants with advanced cancer. The drug is not yet approved by regulatory authorities.
177Lu-3050 targets fibroblast activation protein (FAP), a protein often overexpressed in the tumor microenvironment of solid tumors. By binding to FAP, the drug aims to deliver a therapeutic radioactive payload directly to cancer cells, potentially limiting damage to healthy tissues.
177Lu-3050 is being developed by Immunome, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol IMNM. The company is conducting clinical trials to evaluate the drug's potential in treating advanced solid malignancies.
177Lu-3050 is in Phase 1 clinical development. The drug is investigational and has not received regulatory approval. A Phase 1 study is currently recruiting participants to assess its safety, tolerability, and preliminary efficacy in patients with advanced cancer.
177Lu-3050 is being studied in a Phase 1 clinical trial with the identifier NCT07505771, titled 'A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer.' This trial is recruiting 105 participants with solid malignancies in the United States, with a minimum age of 18 years.
Yes, 177Lu-3050 is also known as 177Lu-IM-3050. Both names refer to the same investigational drug being developed by Immunome, Inc. for the treatment of solid malignancies.